Date:2/17/2010

ures, and tumors of the cervical, thoracic and lumbar spine.  He has extensive experience in clinical research involving the areas of minimally invasive surgery, clinical outcomes of different surgical procedures, and imaging modalities of the spine. His interests include basic science aspects of bone, disc and nerve tissue regeneration as well as the investigation of alternatives to spinal fusion for the treatment of degenerative disc disease.  Dr. Girardi is Associate Attending Orthopaedic Surgeon at the Hospital for Special Surgery and Associate Professor of Orthopedics at Weill Cornell Medical College.  He earned his medical degree at Universidad Nacional de Rosario in Argentina and served his residency at Buenos Aires University in orthopedic surgery and trauma in Buenos Aires, Argentina.  His fellowship was served in the Hospital for Special Surgery, Spine & Scoliosis Surgery in New York.  

Jeffrey Dunn, President and Chief Executive Officer of SI-BONE, commented, "We are honored that these world-renowned specialists have agreed to join SI-BONE's Medical Advisory Board. They all bring extensive clinical experience and a very patient-centric intense focus to our Medical Advisory Board. We expect to benefit from their insights and expertise as we continue to seek to position MIS SI Joint fusion among the frontline therapies for patients with unresolved chronic low back symptoms refractory to conservative medical therapy.  Our MAB members have already assisted with the development of our recently announced strategies to reach out to other spine surgeons and pain specialists, and we look forward to their further contributions in 2010 and beyond."

In response to increasing awareness of SI Joint dysfunction as a debilitating symptom generator, SI-BONE, Inc. developed an
'/>"/>

SOURCE SI-BONE, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Combined Pharma Event Visitor Numbers 5% Ahead of 2008 Frankfurt Record
2. Impact Medical Solutions Announces Initiation of Pilot Clinical Trial and Listing on Frankfurt Stock Exchange
3. Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse
4. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
5. Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center
6. NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer
7. Help is Here Express Arrives in Anderson, Seneca
8. HS-7 Document Regarding Research @ M. D. Anderson Orlando
9. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
10. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
11. Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center